Phase 1/2, Open-label, Dose-escalation Study of IONIS-STAT3Rx, Administered to Patients With Advanced Cancers

NCT01563302 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

64

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Cancers
DLBCL
Lymphoma

Interventions

DRUG: IONIS-STAT3Rx

Sponsor

Ionis Pharmaceuticals, Inc.

Collaborators

[object Object]